Literature DB >> 30905718

Alterations in Skin Microbiomes of Patients With Cirrhosis.

Jasmohan S Bajaj1, Andrew Fagan2, Masoumeh Sikaroodi3, Genta Kakiyama2, Hajme Takei4, Yordanos Degefu3, William M Pandak2, Phillip B Hylemon2, Michael Fuchs2, Binu John2, Douglas M Heuman2, Edith Gavis2, Hiroshi Nittono4, Rohan Patil3, Patrick M Gillevet3.   

Abstract

BACKGROUND & AIMS: Patients with cirrhosis have intestinal dysbiosis and are prone to itching and skin or soft-tissue infections. The skin microbiome, and its relationship with intestinal microbiome, have not been characterized. We investigated alterations in skin microbiota of patients with cirrhosis and their association with intestinal microbiota and modulators of itch.
METHODS: We collected skin swabs at 7 sites and blood and stool samples from 20 healthy individuals (control subjects; mean age, 59 years) and 50 patients with cirrhosis (mean age, 61 years; mean model for end-stage disease score, 12; 20 with decompensation). Skin and stool samples were analyzed by 16s rRNA sequencing and serum samples were analyzed by liquid chromatography and mass spectrometry for levels of bile acids (BAs) and by an ELISA for autotaxin (an itch modulator). Participants were analyzed by the visual analog itch scale (VAS, 0-10,10 = maximum intensity). Data were compared between groups (cirrhosis vs control subjects, with vs without decompensation, VAS 5 or higher vs less than 5). Correlation networks between serum levels of BAs and skin microbiomes were compared between patients with cirrhosis with vs without itching.
RESULTS: The composition of microbiomes at all skin sites differed between control subjects and patients with cirrhosis and between patients with compensated vs decompensated cirrhosis. Skin microbiomes of patients with cirrhosis (especially those with decompensation) contained a higher relative abundance of Gammaproteobacteria, Streptococaceae, and Staphylococcaceae, and fecal microbiomes contained a higher relative abundance of Gammaproteobacteria, than control subjects. These bacterial taxa were associated with serum levels of autotaxin and BAs, which were higher in patients with VAS scores ≥5. Based on network statistics, microbial and BA interactions at all sites were more complex in patients with greater levels of itching in the shin, the most common site of itch.
CONCLUSIONS: We identified alterations in skin microbiome of patients with cirrhosis (in Gammaproteobacteria, Streptococcaceae, and Staphylococcaceae)-especially in patients with decompensation; fecal microbiomes of patients with cirrhosis had a higher relative abundance of Gammaproteobacteria than control subjects. These specific microbial taxa are associated with itching intensity and itch modulators, such as serum levels of BAs and autotaxin.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dermatology; Dysbiosis; Patient-Reported Outcome; Pruritus; Saliva

Mesh:

Substances:

Year:  2019        PMID: 30905718      PMCID: PMC6754819          DOI: 10.1016/j.cgh.2019.03.028

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  37 in total

1.  Lysophosphatidic acid is a potential mediator of cholestatic pruritus.

Authors:  Andreas E Kremer; Job J W W Martens; Wim Kulik; Franziska Ruëff; Edith M M Kuiper; Henk R van Buuren; Karel J van Erpecum; Jurate Kondrackiene; Jesus Prieto; Christian Rust; Victoria L Geenes; Catherine Williamson; Wouter H Moolenaar; Ulrich Beuers; Ronald P J Oude Elferink
Journal:  Gastroenterology       Date:  2010-06-19       Impact factor: 22.682

2.  Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation.

Authors:  Jasmohan S Bajaj; Phillip B Hylemon; Jason M Ridlon; Douglas M Heuman; Kalyani Daita; Melanie B White; Pamela Monteith; Nicole A Noble; Masoumeh Sikaroodi; Patrick M Gillevet
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-07-19       Impact factor: 4.052

3.  Cellular basis of itch sensation.

Authors:  Yan-Gang Sun; Zhong-Qiu Zhao; Xiu-Li Meng; Jun Yin; Xian-Yu Liu; Zhou-Feng Chen
Journal:  Science       Date:  2009-08-06       Impact factor: 47.728

Review 4.  Pruritus in chronic cholestatic liver disease.

Authors:  Chalermrat Bunchorntavakul; K Rajender Reddy
Journal:  Clin Liver Dis       Date:  2012-05       Impact factor: 6.126

5.  Modulation of the fecal bile acid profile by gut microbiota in cirrhosis.

Authors:  Genta Kakiyama; William M Pandak; Patrick M Gillevet; Phillip B Hylemon; Douglas M Heuman; Kalyani Daita; Hajime Takei; Akina Muto; Hiroshi Nittono; Jason M Ridlon; Melanie B White; Nicole A Noble; Pamela Monteith; Michael Fuchs; Leroy R Thacker; Masoumeh Sikaroodi; Jasmohan S Bajaj
Journal:  J Hepatol       Date:  2013-01-16       Impact factor: 25.083

6.  Topographical and temporal diversity of the human skin microbiome.

Authors:  Elizabeth A Grice; Heidi H Kong; Sean Conlan; Clayton B Deming; Joie Davis; Alice C Young; Gerard G Bouffard; Robert W Blakesley; Patrick R Murray; Eric D Green; Maria L Turner; Julia A Segre
Journal:  Science       Date:  2009-05-29       Impact factor: 47.728

7.  Risk factors for the outcome of cirrhotic patients with soft tissue infections.

Authors:  Ber-Ming Liu; Kun-Jung Chung; Chien-Hung Chen; Chia-Te Kung; Sheung-Fat Ko; Po-Ping Liu; Hsueh-Wen Chang
Journal:  J Clin Gastroenterol       Date:  2008-03       Impact factor: 3.062

8.  Alterations of the human gut microbiome in liver cirrhosis.

Authors:  Nan Qin; Fengling Yang; Ang Li; Edi Prifti; Yanfei Chen; Li Shao; Jing Guo; Emmanuelle Le Chatelier; Jian Yao; Lingjiao Wu; Jiawei Zhou; Shujun Ni; Lin Liu; Nicolas Pons; Jean Michel Batto; Sean P Kennedy; Pierre Leonard; Chunhui Yuan; Wenchao Ding; Yuanting Chen; Xinjun Hu; Beiwen Zheng; Guirong Qian; Wei Xu; S Dusko Ehrlich; Shusen Zheng; Lanjuan Li
Journal:  Nature       Date:  2014-07-23       Impact factor: 49.962

Review 9.  Microbiome in the Gut-Skin Axis in Atopic Dermatitis.

Authors:  So Yeon Lee; Eun Lee; Yoon Mee Park; Soo Jong Hong
Journal:  Allergy Asthma Immunol Res       Date:  2018-07       Impact factor: 5.764

10.  A real-world observational cohort of patients with primary biliary cholangitis: TARGET-primary biliary cholangitis study design and rationale.

Authors:  Cynthia Levy; Christopher L Bowlus; Elizabeth Carey; Julie M Crawford; Karen Deane; Marlyn J Mayo; W Ray Kim; Michael W Fried
Journal:  Hepatol Commun       Date:  2018-03-23
View more
  6 in total

Review 1.  THE SKIN MICROBIOTA AND ITCH: Is There a Link?

Authors:  Hei Sung Kim; Gil Yosipovitch
Journal:  J Clin Aesthet Dermatol       Date:  2020-06-01

2.  Stool microbiota are superior to saliva in distinguishing cirrhosis and hepatic encephalopathy using machine learning.

Authors:  Krishnakant Saboo; Nikita V Petrakov; Amirhossein Shamsaddini; Andrew Fagan; Edith A Gavis; Masoumeh Sikaroodi; Sara McGeorge; Patrick M Gillevet; Ravishankar K Iyer; Jasmohan S Bajaj
Journal:  J Hepatol       Date:  2021-11-15       Impact factor: 25.083

Review 3.  Predictive value of serum bile acids as metabolite biomarkers for liver cirrhosis: a systematic review and meta-analysis.

Authors:  Xu Han; Juan Wang; Hao Gu; Hongtao Guo; Yili Cai; Xing Liao; Miao Jiang
Journal:  Metabolomics       Date:  2022-06-27       Impact factor: 4.747

4.  Predictive value of liver cirrhosis using metabolite biomarkers of bile acid in the blood: A protocol for systematic review and meta-analysis.

Authors:  Xu Han; Juan Wang; Hao Gu; Xing Liao; Miao Jiang
Journal:  Medicine (Baltimore)       Date:  2022-01-28       Impact factor: 1.889

Review 5.  Bile Acid Receptors and the Gut-Liver Axis in Nonalcoholic Fatty Liver Disease.

Authors:  Rui Xue; Lianyong Su; Shengyi Lai; Yanyan Wang; Derrick Zhao; Jiangao Fan; Weidong Chen; Phillip B Hylemon; Huiping Zhou
Journal:  Cells       Date:  2021-10-20       Impact factor: 7.666

Review 6.  The Skin Microbiota and Itch: Is There a Link?

Authors:  Hei Sung Kim; Gil Yosipovitch
Journal:  J Clin Med       Date:  2020-04-22       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.